Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
| ▸ | GLI1 | P08151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3666260 | 1.00 | GRM2 (0.38) | GRM2GRM3CYP1A2ALOX15CTSC | |
| SCHEMBL3666263 | 1.00 | GRM2 (0.38) | GRM2GRM3CYP1A2ALOX15CTSC | |
| Hydrochloric Acid SCHEMBL1347345 | 0.98 | GRM2 (0.37) | GRM2GRM3CYP1A2ALOX15CTSC | |
| Hydrochloric Acid SCHEMBL15776372 | 0.98 | GRM2 (0.37) | GRM2GRM3CYP1A2ALOX15CTSC | |
| Hydrochloric Acid SCHEMBL6826204 | 0.98 | GRM2 (0.37) | GRM2GRM3CYP1A2ALOX15CTSC | |
| Trifluoroacetic Acid SCHEMBL15129828 | 0.89 | GRM2 (0.36) | GRM2GRM3CYP1A2ALOX15CTSC | |
| SCHEMBL24021079 | 0.80 | GRM2 (0.34) | GRM2GRM3CYP1A2ALOX15 | |
| SCHEMBL40622 | 0.80 | CYP1A2 (0.53) | GRM2GRM3CYP1A2ALOX15CTSC | |
| SCHEMBL3145095 | 0.80 | CYP1A2 (0.53) | GRM2GRM3CYP1A2ALOX15CTSC | |
| SCHEMBL40623 | 0.80 | CYP1A2 (0.53) | GRM2GRM3CYP1A2ALOX15CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353817-A1 | INTERLUKIN-17A INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353817-A1 | INTERLUKIN-17A INHIBITORS AND USES THEREOF | IL17A, IL15, IL23R | GRM2 4632/4885GRM3 4437/4885CYP1A2 625/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | GRM2 2373/4885GRM3 2907/4885CYP1A2 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.